Corporate Presentation. August 2018

Transcription

1 Corporate Presentation August 2018

2 Outline About Menarini Group Menarini Asia-Pacific Partnering as a Model for Success Our Adantage 2

3 About Menarini Group Oeriew of Menarini Group R&D and Manufacturing Established Partnership Record 3

4 Oeriew of Menarini Group Number 1 Italian biopharmaceutical company Founded in 1886 Priately owned, headquartered in Florence, Italy Ranks 13 th out of 5,345 companies in Europe and 35 th out of 21,587 companies worldwide Pharmaceuticals, Biotech, and Medical Diagnostics 6 R&D centers and 16 manufacturing plants 2017 turnoer > EUR 3.6billion with oer 17,000 employees 4

5 Sales & Marketing Presence Menarini is present in more than 100 countries oerall, through affiliates, distributors or licenses. 5

6 Manufacturing and R&D in Europe R&D expertise in both small molecule and biological therapeutics Significant manufacturing presence across Europe Kaluga Shannon Berlin Dresden Milan Pisa Barcelona L Aquila Istanbul Legend Manufacturing Manufacturing and R&D Centres 6

7 Established Partnership Record 7

8 About Menarini Asia-Pacific Oeriew of Menarini Asia-Pacific Key Therapeutic Areas Management Team 8

9 Oeriew of Menarini Asia-Pacific A leading biopharmaceutical company specialized in commercialising differentiated healthcare brands across the Asia-Pacific region Formed in 2005 ia tripartite JV Acquired by Menariniin Noember 2011 and rebranded in 2012 Headquartered in Singapore Broad geographic coerage across 13 major markets in Asia-Pacific (ex-japan) Oer 3000 employees; nearly 80% sales and marketing personnel Established Clinical Deelopment, Regulatory, Medical Marketing, Sales and support functions with execution success across all markets Dierse portfolio of proprietary and partnered brands in a wide range of TAs 9

10 Key Therapeutic Areas Allergy/Respiratory Cardioascular Dermatology Gastroenterology Men s Health Pain Select Specialty Care Consumer Health 10

11 Regional Management Committee Albert Lim Chief Executie Officer Christopher Tay Chief Administratie Officer Ho Long Shiuan Vice President Finance Mark Brown Vice President, AU, NZ, IN, ID, PH BI, Key Account Brett Hayes Vice President HK, TH, VN MA, RA, QA Albert Kim Vice President KR, MY, SG, TW Commercial Training Tom Browning Vice President Medical Marketing Valerie Lau Vice President Consumer Health Marco Vanoli Vice President SFE & FFOE Nader Rostom Corporate Director Frontier Markets Sandro Casini Corporate Director Alliance Management Paolo Volpi Corporate Director Business Deelopment

12 Partnering as a Model for Success Core Competencies Featured Proprietary Brands Key Partnerships Deelopment 12

13 Core Competencies Clinical Operations Regulatory Affairs Quality Affairs Medical Affairs Commercialization Experience in Phase I to III clinical trial management across different therapeutic areas Experience in managing local bridging studies for registrations in India, China, Korea and Taiwan Good partnerships with well established ICH GCP recognised CROs. Extensie experience across 21 markets. Successful market access through new registrations in products across Pharma, Deice, Cosmetics and Supplements Life Cycle Management of existing licenses In country local regulatory teams Strong track record managing registrations in the dynamic APAC regulatory enironment Strong QMS systems in place GDPMDS and ISO Regular audits of distribution partners Regular audits of manufacturers Strong commercial QA support of supply chain and logistics Well managed Pharmaco Vigilance systems and processes. Oersight on promotional material approals Commercial team product training Management of medical information and customer queries Medical publications management 2,200+ sales force Market Intelligence Eidence Based Medical Marketing Marketing Excellence and Launch Readiness Alliance Management Supply Chain / Logistics 13

14 Featured Brands Allergy / Respiratory Cardioascular Dermatology Gastroenterology Men s Health Pain Selected Specialty Consumer Health Neurology Women s Health Oncology 14

15 Key Partnership Deelopment Extensions of existing partnerships not captured in timeline 15

16 Our Adantage Unique Value Proposition 16

17 A Unique Value Proposition Gateway to Asia-Pacific (one stop solution) Strong Sales, Marketing and Regulatory Footprint Flexible Business Model Broad Therapeutic Expertise Full suite of capabilities from R&D through Sales 17

18